{"id":212114,"date":"2026-05-30T05:25:42","date_gmt":"2026-05-30T05:25:42","guid":{"rendered":"https:\/\/quixnet.net\/wpinstance\/groundbreaking-genomic-test-could-spare-millions-of-breast-cancer-patients-chemotherapy-the-guardian\/"},"modified":"2026-05-30T05:25:42","modified_gmt":"2026-05-30T05:25:42","slug":"groundbreaking-genomic-test-could-spare-millions-of-breast-cancer-patients-chemotherapy-the-guardian","status":"publish","type":"post","link":"https:\/\/quixnet.net\/wpinstance\/groundbreaking-genomic-test-could-spare-millions-of-breast-cancer-patients-chemotherapy-the-guardian\/","title":{"rendered":"Groundbreaking genomic test could spare millions of breast cancer patients chemotherapy – The Guardian"},"content":{"rendered":"
    \n
  1. Groundbreaking genomic test could spare millions of breast cancer patients chemotherapy<\/a>  The Guardian<\/font><\/li>\n
  2. Veracyte genomic test identifies breast cancer patients who can skip chemo<\/a>  Reuters<\/font><\/li>\n
  3. Genetic test could offer breast cancer patients chance to skip chemo<\/a>  The Times<\/font><\/li>\n
  4. Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte\u2019s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy<\/a>  Business Wire<\/font><\/li>\n
  5. OPTIMA Phase III: Gene Expression Test Helps Identify Patients Who May Avoid Chemotherapy<\/a>  Docwire News<\/font><\/li>\n<\/ol>\n

    source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

    Groundbreaking genomic test could spare millions of breast cancer patients chemotherapy  The Guardian Veracyte genomic test identifies breast cancer patients who can skip chemo  Reuters Genetic test could offer breast cancer patients chance to skip chemo  The Times Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte\u2019s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid […]<\/p>\n","protected":false},"author":1,"featured_media":212115,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":"","footnotes":""},"categories":[4],"tags":[],"class_list":{"0":"post-212114","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-breaking-news-video","8":"entry"},"_links":{"self":[{"href":"https:\/\/quixnet.net\/wpinstance\/wp-json\/wp\/v2\/posts\/212114","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/quixnet.net\/wpinstance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/quixnet.net\/wpinstance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/quixnet.net\/wpinstance\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/quixnet.net\/wpinstance\/wp-json\/wp\/v2\/comments?post=212114"}],"version-history":[{"count":0,"href":"https:\/\/quixnet.net\/wpinstance\/wp-json\/wp\/v2\/posts\/212114\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/quixnet.net\/wpinstance\/wp-json\/wp\/v2\/media\/212115"}],"wp:attachment":[{"href":"https:\/\/quixnet.net\/wpinstance\/wp-json\/wp\/v2\/media?parent=212114"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/quixnet.net\/wpinstance\/wp-json\/wp\/v2\/categories?post=212114"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/quixnet.net\/wpinstance\/wp-json\/wp\/v2\/tags?post=212114"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}